Compare ADMA Biologics Inc (ADMA) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Sirius XM Holdings Inc — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while Sirius XM Holdings Inc trades at $30.22 (market cap $10.34B). The key difference: Sirius XM Holdings Inc is far larger — about 4.9× ADMA Biologics Inc's market cap, and Sirius XM Holdings Inc pays a 3.52% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | SIRI | |
|---|---|---|
Market Cap | $2.13B | $10.34B |
Sector | Health | Media |
52-Week High | $20.38 | $30.75 |
52-Week Low | $7.60 | $19.92 |
Enterprise Value | $2.20B | $20.01B |
Dividend Yield | — | 3.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Sirius XM (SIRI) trades at $30.71, up 0.66% on the day, with a bullish technical signal from moving averages. The stock shows solid fundamentals with a P/E of 13.03 and a net income margin of 9.86%, supported by recent earnings beats. Analysts maintain a consensus Buy rating with a $31.17 price target, and the company continues to generate strong operating cash flow of $1.90B in 2025. Recent news highlights a new advertising partnership with Alphabet and upcoming Q2 2026 earnings.
The outlook for SIRI is positive, driven by consistent earnings performance and strategic partnerships. Key opportunities include dividend yield and potential index inclusion benefits. Risks involve high debt levels and competitive pressures in the media sector. The stock's current price near the consensus target suggests limited upside unless earnings exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
